Please wait while we load the requested 10-K report or click the link below:
WAVE Life Sciences Reports Fourth Quarter and Full Year 2015 Financial Results and
Provides Business Update
On track to file two INDs for lead programs in Huntingtons disease in 2016;
Advancing over 20 discovery programs for genetically defined rare and other serious diseases
Strong financial position; existing cash to support pipeline progression, clinical programs
and operations well into 2018
CAMBRIDGE, Mass. (BUSINESS WIRE) March 30, 2016 WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing stereopure nucleic acid therapies to deliver new and exceptional treatment options for patients impacted by genetic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2015 and provided a business update.
2015 was a year of tremendous growth for WAVE. We laid a solid foundation to support our planned expansion in 2016 and beyond. Our successful Series A financing, Series B financing and IPO have provided us with the financial resources to advance our pipeline and commence multiple clinical programs over the next three years, said Paul Bolno, M.D., MBA, President and Chief Executive Officer at WAVE Life Sciences. We continue to attract world-class talent to join a team dedicated to making meaningful medicines for patients.
Recent Highlights and Outlook
|||Announced plan to deliver six clinical programs by 2018. WAVE plans to bring multiple novel genetic therapies into the clinic over the next three years. Based on its proprietary stereopure chemistry platform, WAVEs current pipeline is comprised of over 20 stereopure antisense, exon skipping, and RNAi programs in early discovery and development across multiple therapeutic areas. WAVEs development efforts are focused on neurological and neuromuscular rare diseases. Its broader pipeline reflects the inherent versatility and diverse therapeutic potential of its platform, including hepatic, ophthalmic, dermatologic and gastrointestinal disease indications.|
|||On track to file two INDs for Huntingtons disease in 2016. WAVE intends to file investigational new drug (IND) applications in 2016 for its two lead allele-targeted antisense programs, each of which distinctly targets the underlying genetic cause of Huntingtons disease (HD). Both programs enable selective silencing of the disease-associated allele by targeting single nucleotide polymorphisms associated with mutated alleles in subsets of patients with HD. This distinctive capability may increase the therapeutic window relative to approaches that are unable to distinguish between alleles.|
The following information was filed by Wave Life Sciences Ltd. (WVE) on Wednesday, March 30, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Wave Life Sciences Ltd.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Wave Life Sciences Ltd..